From MS to NMOSD to early Alzheimer's disease, neurologic mAbs are delivering proven clinical benefit. But as efficacy becomes less of a differentiator, what determines whether these therapies reach patients? In this art...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Real-World Evidence in transition: CRO adaptation to the European Health Data Space framework
This article explores how the European Health Data Space (EHDS) is transforming real-world evidence generation by shifting CROs from data custodians to regulated data users operating within secure, interoperable environments, creating new opportunities for pan-European research while requiring greater investment in compliance, data standardisation and methodological rigour.
-
Chinese drugmakers with big ambitions struggle to recruit staff for global expansion
China's rapid rise as a hub for testing experimental, next-generation medicines is outpacing the industry's ability to build the workforce needed to take those products global.
-
Clinical success for CNS mAbs depends on more than mechanisms of action alone
The success of CNS monoclonal antibodies (mAbs) depends on more than innovative science. Robust clinical operations and safety governance are critical to protecting patients and advancing development. Discover the key operational considerations for neurologic mAbs in the article.
-
Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
Examine how accelerated approvals can unlock earlier market access and why weak biomarker foundations, self-competitive confirmatory trials and payer misalignment remain critical risks.
-
It’s complicated! When APAC global ambition meets regulatory reality
While not all sponsors plan to market treatments beyond the country of origin, many do. Those sponsors with global ambitions must decide which regulatory route offers the most strategic advantages and which market, particularly between the EU and US.
-
June 2026 Medical/ Commercial Pulse Check
With the first EU JCAs finalized and CMS extending deadlines for its ambitious Medicaid international-pricing model, ICON and other industry leaders share how they are navigating the friction between global harmonization and local execution including the practical evolution of global pricing floors, the maturing role of AI agents, and the new reality of European access.
-
The Next Wave of Biosimilars: Why Hematology Is a High-Stakes Opportunity
A confluence of patent expiries and rising healthcare costs are accelerating both interest and investment in biosimilars across the world. In this article on Citeline we discuss how this relates to one of the major impacted areas, hematology.
-
When your CRO’s AI platform upgrades, who pays for the change management?
This article examines the operations and cost considerations of ICON’s AI platform evolution, following it’s partnership with Microsoft to scale the Orbis platform across clinical trials.
-
ICON names Microsoft tech partner as Q1 results grow analyst confidence
This article reports on ICON naming Microsoft as a technology partner to scale its Orbis AI platform, while highlighting growing analyst confidence driven by improving performance and demand.
-
Biosimilar Success in an Evolving Landscape: Development Considerations for Staying Competitive
Regulatory pathways for biosimilars are changing, with reduced clinical requirements placing greater emphasis on analytical comparability and manufacturing excellence. Understanding how to respond to these shifts can make the difference between speed to market and costly delays. Explore the key considerations shaping today’s biosimilars landscape in ICON's latest article.
